Meropur (Menotrophin)

Menotropin provides equal amounts of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). After subcutaneous injection it binds to FSH and LH receptors on ovarian cells, triggering signalling pathways that promote follicle growth, estrogen production and the final release of a mature oocyte.

The dose of Meropur is individualized. A qualified prescriber determines the amount, frequency and duration of treatment based on the patient’s ovarian response, the specific assisted‑reproduction protocol and other clinical factors.

Meropur is intended for use before conception to stimulate ovulation. It is not used during an established pregnancy, and safety in breastfeeding has not been established. Women should discuss reproductive plans with their healthcare provider before starting therapy.

To order Meropur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Meropur delivers a fixed combination of FSH and LH activity, whereas some alternatives provide only FSH (e.g., recombinant FSH) or separate LH preparations. The combined profile can simplify dosing for protocols that require both hormones, but the choice depends on the clinician’s protocol, patient response and cost considerations.

Meropur should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use to maintain stability and potency.

Meropur is supplied as a sterile solution for subcutaneous injection. The injection is typically given into the abdominal wall or thigh, following aseptic technique and the dosing schedule prescribed by the treating physician.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause abdominal pain, fluid accumulation and, in severe cases, thromboembolic events, as well as the possibility of multiple pregnancy and rare severe allergic reactions. Patients should be monitored closely for these complications.

Meropur is contraindicated in women who are already pregnant, have known hypersensitivity to menotropin or any excipients, have active ovarian cysts, or have hormone‑sensitive malignancies unless specifically advised by a specialist. It should also be used with caution in patients with severe renal or hepatic impairment.